Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Index- P/E26.95 EPS (ttm)2.03 Insider Own- Shs Outstand2.66B Perf Week3.83%
Market Cap145.63B Forward P/E14.12 EPS next Y3.88 Insider Trans- Shs Float2.37B Perf Month4.65%
Income5.42B PEG3.13 EPS next Q- Inst Own9.10% Short Float0.07% Perf Quarter3.11%
Sales43.51B P/S3.35 EPS this Y-25.80% Inst Trans0.52% Short Ratio1.43 Perf Half Y11.66%
Book/sh26.09 P/B2.10 EPS next Y10.87% ROA4.20% Target Price59.48 Perf Year15.38%
Cash/sh2.15 P/C25.46 EPS next 5Y8.60% ROE7.50% 52W Range45.30 - 55.35 Perf YTD5.70%
Dividend1.91 P/FCF- EPS past 5Y-1.20% ROI6.10% 52W High-1.17% Beta1.06
Dividend %3.49% Quick Ratio1.40 Sales past 5Y2.90% Gross Margin67.10% 52W Low20.74% ATR0.85
Employees112128 Current Ratio1.40 Sales Q/Q0.70% Oper. Margin20.90% RSI (14)59.36 Volatility1.26% 1.13%
OptionableYes Debt/Eq0.29 EPS Q/Q77.30% Profit Margin12.60% Rel Volume0.66 Prev Close54.70
ShortableYes LT Debt/Eq0.20 EarningsFeb 09 BMO Payout41.00% Avg Volume1.08M Price54.70
Recom1.70 SMA202.98% SMA503.80% SMA2007.41% Volume715,932 Change0.00%
03-Aug-12Downgrade Standpoint Research Buy → Hold
11-Jan-11Downgrade Jefferies Buy → Hold
16-Nov-09Initiated Deutsche Securities Buy
14-Oct-09Upgrade UBS Sell → Neutral
28-Aug-09Upgrade JP Morgan Neutral → Overweight
29-Jun-09Downgrade JP Morgan Overweight → Neutral
28-May-09Upgrade Citigroup Hold → Buy
30-Apr-09Upgrade JP Morgan Neutral → Overweight
23-Mar-09Upgrade Jefferies & Co Underperform → Hold
17-Mar-09Initiated Credit Suisse Outperform
19-Feb-09Upgrade JP Morgan Underweight → Neutral
26-Jan-09Initiated Jefferies & Co Underperform
07-Nov-08Downgrade UBS Neutral → Sell
23-Sep-08Downgrade Credit Suisse Neutral → Underperform
24-Oct-07Initiated Bernstein Mkt Perform
06-Sep-07Initiated UBS Neutral
18-Jul-07Upgrade HSBC Securities Neutral → Overweight
14-Jun-07Reiterated Banc of America Sec Buy $50 → $48
14-Jun-07Downgrade JP Morgan Overweight → Neutral
14-Jun-07Downgrade HSBC Securities Overweight → Neutral
29-Aug-14 05:30PM  Regeneron Pharmaceuticals' Pipeline Progress Raises Costs Zacks
28-Aug-14 03:17PM  Amgen: Why Its New Drug Application is a Big Deal at Barrons.com
03:17PM  Amgen: Why Its New Drug Application is a Bid Deal at Barrons.com
10:38AM  There Are 2000 Reasons For Continued Optimism In The Stock Market at Forbes
08:25AM  The Zacks Analyst Blog Highlights: RadioShack, Amicus Therapeutics, Sanofi, Shire and Gilead Sciences Zacks
27-Aug-14 07:00AM  Where Are the Opportunities in U.S. Health Care? Morningstar
03:17AM  Return to Behemoth Stocks Yahoo Finance Blogs
25-Aug-14 04:03PM  The 4 Companies Teaming Up For A New Tool To Fight Cancer Benzinga
11:40AM  InterMune Stock Spikes On Rare Big Biotech Buyout at Investor's Business Daily
01:00AM  Regeneron and Sanofi to Present Results from Four Phase 3 Alirocumab Trials in Hot Line Session at ESC Congress 2014 PR Newswire
22-Aug-14 05:15PM  Covance Retains Balanced View on Steady Growth Zacks
04:00PM  AstraZeneca Updates on PLATO Study Investigation on Brilinta Zacks
08:24AM  Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day Zacks
21-Aug-14 03:55PM  Amicus Therapeutics (FOLD) Soars on Fabry Drug Trial Results Zacks
03:47PM  5 companies that will benefit from ALS awareness at MarketWatch
02:30PM  Illumina Partners with AstraZeneca, Sanofi, Janssen in NGS Zacks
12:03PM  Video: Illumina Partners With Big Pharma Firms at Investor's Business Daily
12:03PM  Illumina Forms Partnerships With Big Pharma Firms at Investor's Business Daily
02:00AM  Illumina Partners With Big PharmaTo Create New Genetic Tests For Cancer at Forbes
02:00AM  Illumina Partners With Big Pharma To Create New Genetic Tests For Cancer at Forbes
20-Aug-14 05:30PM  Sanofi's (SNY) Cerdelga FDA Approved for Gaucher Disease Zacks
06:05AM  Amicus Releases Study Results On Rare Disease Drug at Forbes
06:05AM  Amicus Releases Strongly Positive Study Results On Rare Disease Drug at Forbes
06:05AM  Amicus Releases Positive Study Results On Rare Disease Drug at Forbes
06:01AM  Yes, Call it a Comeback: Amicus Fabry Drug Posts Big Study Win at TheStreet
19-Aug-14 04:45PM  FDA Approves Genzymes Cerdelga (eliglustat) Capsules Business Wire
12:10PM  Eli Lilly-Boehringer's Insulin Drug Gets Tentative FDA Nod Zacks
18-Aug-14 08:13AM  Washington Post Off Base In Critiquing Pharma Efforts In Ebola at Forbes
15-Aug-14 09:41AM  Story Stocks from Briefing.com Briefing.com
08:59AM  Story Stocks from Briefing.com Briefing.com
07:14AM  Story Stocks from Briefing.com Briefing.com
14-Aug-14 04:00PM  Merck's Insomnia Drug Belsomra Approved by the FDA Zacks
09:33AM  Stock Market News for August 14, 2014 Zacks
08:46AM  Story Stocks from Briefing.com Briefing.com
08:14AM  Why InterMune (ITMN) Stock Is Down Today at TheStreet
07:44AM  Story Stocks from Briefing.com Briefing.com
13-Aug-14 05:00PM  Sanofi Pasteur Announces Publication of Positive Data for Fluzone® High-Dose Vaccine in The New England Journal of Medicine PR Newswire
12:04PM  Blame MannKind's Fall on its Bloated Balance Sheet at TheStreet
09:53AM  What the Market is Telling MannKind at 24/7 Wall St.
09:08AM  Story Stocks from Briefing.com Briefing.com
08:16AM  Story Stocks from Briefing.com Briefing.com
06:59AM  Story Stocks from Briefing.com Briefing.com
12-Aug-14 10:10AM  Did MannKind Find Right Afrezza Partner in Sanofi? at Barrons.com
10:05AM  MannKind Posts Wider Q2 Loss, Up on Sanofi Deal for Afrezza Zacks
09:59AM  Story Stocks from Briefing.com Briefing.com
08:50AM  Sanofi Launches Authorized Generic Version of Eloxatin® (oxaliplatin injection) PR Newswire
07:24AM  Story Stocks from Briefing.com Briefing.com
11-Aug-14 04:20PM  MannKind Enters into a Global Deal with Sanofi for Afrezza Zacks
12:36PM  [video] Sanofi to Pay MannKind as Much as $925M for Afrezza Global Rights at TheStreet
11:48AM  Jim Cramer's Mad Dash: Good News for Tesla and MannKind at TheStreet
11:25AM  U.S. stocks rise; Kinder Morgan jumps at MarketWatch
10:10AM  MannKind shares soar on Sanofi deal; investors ignore earnings report at MarketWatch
09:59AM  Story Stocks from Briefing.com Briefing.com
09:39AM  U.S. stocks open higher; Kinder Morgan jumps at MarketWatch
09:24AM  Kinder Morgan, MannKind soar; Dean Foods sinks at MarketWatch
09:11AM  MannKind Secures Future of Afrezza in Major Sanofi Deal at 24/7 Wall St.
09:09AM  Priceline's outlook disappoints; Kinder Morgan unites; MannKind shares rocket Hot Stock Minute
09:03AM  U.S. stocks: Futures rise after Fischers dovish remarks at MarketWatch
08:29AM  Stock Market Today: Stock Futures Rise Amid Renewed Dip-Buying TheStreet
08:20AM  Why ManKind (MNKD) Stock Is Soaring Today at TheStreet
08:05AM  MannKind Shares Explode After Announcing Inhaled Insulin Deal Business Insider
08:05AM  MannKind Shares Explode After Announcing Inhaled Insulin Deal Business Insider
07:47AM  U.S. stocks: Futures up after Fischer hints at loose monetary policy at MarketWatch
07:46AM  U.S. stocks: Futures up after Fischer hinst at loose monetary policy at MarketWatch
07:38AM  Kinder Morgan, MannKind Corp soar; Priceline retreats at MarketWatch
07:36AM  Stock Market Today: Stock Futures Higher, Markets Take Breather From Geopolitical Jitters TheStreet
07:27AM  Story Stocks from Briefing.com Briefing.com
07:00AM  Sanofi and MannKind Announce Global Licensing Agreement for Afrezza® (insulin human) Rapid-Acting Inhaled Insulin PR Newswire
06:49AM  MannKind Lands Afrezza Partner but at High Cost at TheStreet
05:50AM  U.S. stocks: Futures up after Fischer says global recovery disappointing at MarketWatch
05:50AM  Priceline, Dean Foods are stocks to watch Monday at MarketWatch
05:32AM  Sanofi, MannKind to commercialize Afrezza insulin therapy at MarketWatch
01:12AM  Sanofi and MannKind Announce Global Licensing Agreement for Afrezza(R) (insulin human) Rapid-Acting Inhaled Insulin GlobeNewswire
09-Aug-14 02:35AM  [$$] 13D Filings at Barrons.com
08-Aug-14 10:00AM  VIVUS Reports Narrower-than-Expected Loss on Qsymia Sales Zacks
07-Aug-14 01:50PM  InterMune Q2 Loss Wider than Expected, Expense Guidance Up Zacks
08:00AM  Sanofi Licenses Immune Design's GLAAS Platform to Explore Novel Approach to Treat Food Allergy GlobeNewswire
05-Aug-14 02:50PM  Regeneron Misses on Earnings in Q2, Eylea Drives Sales Beat Zacks
09:16AM  Pfizer To Buy Baxter's Vaccines For $635 Million: The Positives & Negatives Benzinga
04-Aug-14 01:50PM  ImmunoGen Q4 Loss Narrower than Expected, Provides Guidance Zacks
10:56AM  Amgen Cancer Drug Kyprolis Succeeds In Trial at Investor's Business Daily
05:59AM  Sanofi and Regeneron Pay $67.5 Million to Fast-Track a Cholesterol Drug at BusinessWeek
01-Aug-14 01:39PM  Genzyme Receives Label Expansion for Lumizyme® (alglucosidase alfa) in the United States for the treatment of Pompe Disease Business Wire
01:03PM  3 Stocks Pushing The Drugs Industry Higher at TheStreet
08:10AM  Sanofi Beats on Q2 Earnings, View Up on Strong Performance Zacks
31-Jul-14 04:00PM  BioMarin Q2 Loss Narrower than Expected, Revenue Guidance Up Zacks
02:12PM  Len Schleifer's Science Focus Pays Off At Regeneron at Investor's Business Daily
11:47AM  Europe closes at 3-week low; inflation data, Portugal weighs at CNBC
11:47AM  Europe closes at 3-week low; infation data, Portugal weighs at CNBC
11:29AM  Europe shares close lower; Portugal down over 3% at CNBC
08:18AM  Europe stocks lower; inflation data misses; Shell bounces 3% at CNBC
08:16AM  Why Sanofi (SNY) Stock Is Gaining Today at TheStreet
08:00AM  Sanofi: Solid Sales and Business EPS Growth at CER PR Newswire
07:37AM  [$$] Regeneron Boosted by Latest Approval at Barrons.com
05:31AM  Europe stocks lower; inflation data misses; Shell bounces 3% at CNBC
03:59AM  Europe stocks edge lower; Shell bounces 3.5% at CNBC
03:00AM  Europe stocks open mixed; Shell shares bounce 2.5% at CNBC
02:28AM  Sanofi H1 2014 Results - Interview with Chris Viehbacher PR Newswire
30-Jul-14 04:01PM  Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission PR Newswire
12:14PM  Midday movers: Hess, Twitter, Valero Eneregy & More at CNBC
Sanofi researches, develops, manufactures, and markets healthcare products. The company operates in three segments: Pharmaceuticals, Human Vaccines, and Animal Health. Its products include Lantus and Apidra analogs of human insulin; Insuman human insulin solutions and suspensions; Amaryl, a sulfonylurea; BGStar, iBGStar, and MyStar Extra blood glucose meters; enzyme replacement therapies, such as Cerezyme for Gaucher disease, Fabrazyme for Fabry, and Myozyme/Lumizyme for Pompe disease; Aldurazyme, for mucopolysaccharidosis Type I; Aubagio, a immunomodulator for multiple sclerosis; Taxotere, a taxane derivative for cancers; Eloxatine for colorectal cancer; and Jevtana for prostate cancer. The company's products also comprise thrombosis medicines, such as Plavix anti-platelet agent for atherothrombotic conditions and Lovenox to prevent and treat deep vein thrombosis; and cardiovascular medicines, including Multaq anti-arrhythmic agent and Aprovel/CoAprovel for hypertension treatments. It also offers Renagel/Renvela for patients with chronic kidney disease on dialysis to treat high phosphorus levels; Synvisc and Synvisc-One viscosupplements to treat pain associated with osteoarthritis; and pediatric and influenza, adult and adolescent booster, meningitis and pneumonia, and travel and endemics vaccines. In addition, the company provides pharmaceuticals and vaccines used by veterinarians, farmers, and pet owners; consumer health care products; and generic medicines. Sanofi distributes its products through its sales force, as well as through physicians, pharmacies, hospitals, distributors, veterinaries, chemists, and wholesalers. It has strategic alliances and collaborations with Bristol-Myers Squibb, Regeneron, Warner Chilcott, Regulus Therapeutics Inc., Medtronic, Inc., UCB S.A., and Illumina, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1970 and is headquartered in Paris, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sanofi10% OwnerJul 15Buy314.92129,10040,656,17622,204,841Jul 17 05:50 PM
Sanofi10% OwnerJul 14Buy318.18150,00047,726,79722,075,741Jul 15 05:45 PM
Sanofi10% OwnerJul 11Buy315.41150,00047,311,83621,925,741Jul 15 05:45 PM
Sanofi10% OwnerJul 10Buy311.08175,00054,439,07321,775,741Jul 14 05:46 PM
Sanofi10% OwnerJul 09Buy308.27195,00060,112,31121,600,741Jul 10 05:45 PM
Sanofi10% OwnerJul 08Buy311.67153,00047,685,74321,405,741Jul 10 05:45 PM
Sanofi10% OwnerJul 07Buy312.90256,70080,320,79521,252,741Jul 08 05:42 PM
Sanofi10% OwnerJul 03Buy311.02100,00031,101,94620,996,041Jul 08 05:42 PM
Sanofi10% OwnerJul 02Buy307.25212,40065,259,55220,896,041Jul 03 06:00 PM
Sanofi10% OwnerJul 01Buy300.20212,40063,761,42120,683,641Jul 03 05:46 PM
Sanofi10% OwnerJun 30Buy282.54212,40060,010,47920,471,241Jul 01 05:39 PM
Sanofi10% OwnerJun 27Buy275.3850,00013,769,09220,258,841Jul 01 05:39 PM
Sanofi10% OwnerMay 19Buy300.04190,75157,233,71620,208,841May 21 05:02 PM
Sanofi10% OwnerMar 28Buy306.73306,94594,149,58320,018,090Mar 31 06:22 PM
Sanofi10% OwnerMar 27Buy311.01306,94595,463,96319,711,145Mar 31 06:21 PM
Sanofi10% OwnerMar 24Buy307.91306,94594,511,73418,790,310Mar 25 06:11 PM
Sanofi10% OwnerMar 21Buy321.22305,11598,008,22218,483,365Mar 25 06:10 PM
Sanofi10% OwnerMar 20Buy328.4157,95719,033,51118,178,250Mar 21 06:21 PM
Sanofi10% OwnerMar 19Buy327.899,7463,195,65118,120,293Mar 21 06:21 PM
Sanofi10% OwnerMar 17Buy328.5560,12819,755,23418,110,547Mar 18 06:58 PM
Sanofi10% OwnerMar 14Buy328.3655,58318,251,21518,050,419Mar 18 06:58 PM
Sanofi10% OwnerMar 12Buy334.69220,99573,964,41217,994,836Mar 14 05:11 PM
Sanofi10% OwnerMar 11Buy332.26180,71060,043,33617,773,841Mar 12 05:36 PM
Sanofi10% OwnerMar 10Buy328.73199,82265,687,43517,593,131Mar 12 05:36 PM
Sanofi10% OwnerMar 07Buy332.51241,81880,405,73317,393,309Mar 10 09:52 PM
Sanofi10% OwnerMar 07Buy316.2069,87322,093,65517,151,491Mar 10 09:51 PM
Sanofi10% OwnerMar 06Buy339.6080,40427,305,54617,081,618Mar 10 09:51 PM
Sanofi10% OwnerMar 03Buy338.12251,59485,070,11817,001,214Mar 05 08:36 PM
Sanofi10% OwnerFeb 07Buy287.3421,9866,317,45516,749,620Feb 10 06:46 PM
Sanofi10% OwnerFeb 06Buy286.70146,52542,008,39016,727,634Feb 10 06:46 PM
Sanofi10% OwnerFeb 05Buy282.00206,97858,367,10716,581,109Feb 06 07:30 PM
Sanofi10% OwnerFeb 04Buy286.44190,28654,504,78916,374,131Feb 06 07:30 PM
Sanofi10% OwnerFeb 03Buy283.46198,05856,141,71916,183,845Feb 04 07:11 PM
Sanofi10% OwnerJan 31Buy289.6610,9143,161,38315,985,787Feb 04 07:11 PM
Sanofi10% OwnerJan 28Buy278.5483,23523,184,32115,974,873Jan 29 08:20 AM
Sanofi10% OwnerJan 27Buy272.9674,68520,386,04415,891,638Jan 29 08:20 AM